Cornea

The epithelium-on cross-linking modality is designed to enable simultaneous, bilateral keratoconus treatment, according to Epion Therapeutics.

Additionally, the company plans to perform cash-saving actions, including a workforce reduction.

OKYO Pharma advances urcosimod for neuropathic corneal pain, targeting a new clinical trial to optimize treatment and registration pathways.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

Viridian plans to submit a biologics license application (BLA) for VRDN-003 by year-end 2026.

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).

Patients with higher exposure to nature and green spaces were significantly less likely to experience dry eye, investigators reported

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

Robotic laser arcuate incisions reduce variability and residual astigmatism.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

The primary end point of the trial was complete resolution of debris after 6 weeks of twice-daily dosing.

Funding will be specifically used to accelerate the clinical development of urcosimod (formerly called OK-101).

Pinguecula is a benign, common degeneration of the conjunctiva that appears as a grey-white-yellow mass on the bulbar conjunctiva.

Loteprednol etabonate ophthalmic suspension, 0.5% is bioequivalent to lotemax ophthalmic suspension, 0.5%, of Bausch & Lomb.

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

Krystal Biotech initiates EMERALD-1 trial for KB801, a redosable eye drop gene therapy.

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline results are expected by the end of Q3 2025.

Careful management of patient expectations is key to achieving optimal outcomes.